1-10 of 10
Eva-Maria Grischke
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract PS17-07: Comparison of an Atezolizumab monotherapy window followed by Atezolizumab and chemotherapy vs. Atezolizumab and chemotherapy alone in high-risk triple-negative breast cancer (TNBC) – a subgroup analysis of the neoadjuvant neoMono trial

Free
Hans-Christian Kolberg, Johannes Schumacher, Ramona Erber, Michael Braun, Peter A. Fasching, Eva-Maria Grischke, Christian Schem, Michael P. Lux, Mustafa Deryal, Oliver Hoffmann, Bernhard Heinrich, Georg Kunz, Kristina Lübbe, Petra Krabisch, Arndt Hartmann, Philip Raeth, Sabine Kasimir-Bauer, Cornelia Kolberg-Liedtke
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (12_Supplement): PS17-07.
https://doi.org/10.1158/1557-3265.SABCS24-PS17-07
Published: 13 June 2025
View article titled, Abstract PS17-07: Comparison of an Atezolizumab monotherapy window followed by Atezolizumab and chemotherapy vs. Atezolizumab and chemotherapy alone in high-risk triple-negative breast cancer (TNBC) – a subgroup analysis of the neoadjuvant neoMono trial
Journal Articles

Abstract P2-11-17: Atezolizumab in combination w/ polychemotherapy w/ or without a pretherapeutic immune therapy window in patients w/ early triple negative breast cancer (eTNBC) & low tumor burden – prospective data from the randomized neoadjuvant neoMono trial

Free
Cornelia Kolberg-Liedtke, Johannes Schumacher, Ramona Erber, Michael Braun, Peter A. Fasching, Eva-Maria Grischke, Christian Schem, Michael P. Lux, Mustafa Deryal, Oliver Hoffmann, Bernhard Heinrich, Georg Kunz, Kristina Lübbe, Petra Krabisch, Arndt Hartmann, Philip Raeth, Sabine Kasimir-Bauer, Hans-Christian Kolberg
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (12_Supplement): P2-11-17.
https://doi.org/10.1158/1557-3265.SABCS24-P2-11-17
Published: 13 June 2025
View article titled, Abstract P2-11-17: Atezolizumab in combination w/ polychemotherapy w/ or without a pretherapeutic immune therapy window in patients w/ early triple negative breast cancer (eTNBC) & low tumor burden – prospective data from the randomized neoadjuvant neoMono trial
Journal Articles

Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer

Open Access
Raphaël Leman, Etienne Muller, Angelina Legros, Nicolas Goardon, Imène Chentli, Alexandre Atkinson, Aurore Tranchant, Laurent Castera, Sophie Krieger, Agathe Ricou, Flavie Boulouard, Florence Joly, Romain Boucly, Aurélie Dumont, Noémie Basset, Florence Coulet, Louise-Marie Chevalier, Etienne Rouleau, Katharina Leitner, Antonio González-Martin, Piera Gargiulo, Hans-Joachim Lück, Catherine Genestie, the PAOLA-1 investigators, Gerhard Bogner, Christian Marth, Edgar Petru, Alexander Reinthaller, Christian Schauer, Paul Sevelda, Lionel D'Hondt, Ignace Vergote, Peter Vuylsteke, Sakari Hietanen, Gabriel Lindahl, Johanna Mäenpää, Trine Jakobi Nøttrup, Ulla Puistola, Sophie Abadie-Lacourtoisie, Jérôme Alexandre, Emilie Boissier, Hugues Bourgeois, Annick Chevalier-Place, Pierre Combe, Cristina Costan, Jérôme Dauba, Laure De Cock, Christophe Desauw, Raymond Despax, Nadine Dohollou, Coraline Dubot, Michel Fabbro, Laure Favier, Anne Floquet, Philippe Follana, Claire Garnier Tixidre, Georges Garnier, Laurence Gladieff, Julien Grenier, Cécile Guillemet, Anne-Claire Hardy-Bessard, Florence Joly, Elsa Kalbacher, Marie-Christine Kaminsky, Jean-Emmanuel Kurtz, Rémy Largillier, Claudia Lefeuvre-Plesse, Anne Lesoin, Charles-Briac Levache, Tifenn L'Haridon, Alain Lortholary, Jean-Pierre Lotz, Jérôme Meunier, Mirerille Mousseau, Marie-Ange Mouret-Reynier, Patricia Pautier, Thierry Petit, Magali Provansal, Eric Pujade-Lauraine, Nadia Raban, Isabelle Ray-Coquard, Manuel Rodrigues, Frédéric Selle, Robert Sverdlin, Youssef Tazi, Benoît You, Bahriye Aktas, Dirk Olaf Bauerschlag, Thomas Beck, Antje Belau, Holger Bronger, Stefan Buchholz, Paul Buderath, Alexander Burges, Ulrich Canzler, Nikolaus de Gregorio, Dominik Denschlag, Max Dieterich, Michael Eichbaum, Ahmed El-Balat, Günter Emons, Peter Fasching, Gabriele Feisel-Schwickardi, Matthias Frank, Michael Friedrich, Eva-Maria Grischke, Martina Gropp-Meier, Lars Hanker, Carla Hannig, Philipp Harter, Annette Hasenburg, Martin Hellriegel, Uwe Herwig, Martin Heubner, Joachim Hulde, Christian Jackisch, Matthias Kögel, Peter Krieger, Thorsten Kühn, Clemens Liebrich, Hans-Joachim Lück, Peter Mallmann, Frederik Marmé, Werner Meier, Voker Möbus, Omar Farag Mohamed, Carolin Nestle-Krämling, Tanja Neunhöffer, Gülten Oskay-Özcelik, Tjoung-Won Park-Simon, Beate Rautenberg, Daniel Rein, Wencke Ruhwedel, Ingo Runnebaum, Jacqueline Sagasser, Barbara Schmalfeldt, Andreas Schneeweiss, Andreas Schnelzer, Heinz Scholz, Jalid Sehouli, Antje Sperfeld, Annette Steckkönig, Hans-Georg Strauß, Oliver Tomé, Jörn Treustedt, Hermann Voß, Arthur Wischnik, Ralf Witteler, Achim Wöckel, Hans-Heinrich Woeltjen, Andreas Zorr, Alessandra Bologna, Nicoletta Colombo, Germana Tognon, Saverio Cinieri, Domenica Lorusso, Anna Maria Mosconi, Sandro Pignata, Antonella Savarese, Giovanni Scambia, Roberto Sorio, Claudio Zamagni, Keiichi Fujiwara, Hiroyuki Fujiwara, Hiroaki Kobayashi, Takashi Matsumoto, Shoji Nagao, Toyomi Satoh, Kan Yonemori, Hiroyuki Yoshida, Raquel Bratos, Cristina Caballero, Yolanda Garica, Antonio González-Martín, Eva Maria Guerra Alia, Susana Hernando, Ana Herrero, Nuria Lainez, Luis Manso, Cristina Martin, Eleonor Murata, Eugenia Ortega, Isabel Palacio, Andres Poveda, Ignacio Romero, Maria Jesús Rubio, Isabelle Ray-Coquard, Eric Pujade-Lauraine, Dominique Vaur
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (21): 4419–4429.
https://doi.org/10.1158/1078-0432.CCR-23-0898
Published: 01 November 2023
View article titled, Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
Open the PDF for Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR− Trial

Open Access
Monika Graeser, Oleg Gluz, Claudia Biehl, Daniel Ulbrich-Gebauer, Matthias Christgen, Jenci Palatty, Sherko Kuemmel, Eva-Maria Grischke, Doris Augustin, Michael Braun, Jochem Potenberg, Rachel Wuerstlein, Katja Krauss, Claudia Schumacher, Helmut Forstbauer, Toralf Reimer, Andrea Stefek, Hans Holger Fischer, Enrico Pelz, Christine zu Eulenburg, Ronald Kates, Hua Ni, Cornelia Kolberg-Liedtke, Friedrich Feuerhake, Hans Heinrich Kreipe, Ulrike Nitz, Nadia Harbeck
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (4): 805–814.
https://doi.org/10.1158/1078-0432.CCR-22-1587
Published: 16 February 2023
View article titled, Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR− Trial
Open the PDF for Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR− Trial in another window
Includes: Supplementary data
Journal Articles

De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial

Available to Purchase
Oleg Gluz, Ulrike Nitz, Cornelia Kolberg-Liedtke, Aleix Prat, Matthias Christgen, Sherko Kuemmel, Mohammad Parsa Mohammadian, Daniel Gebauer, Ronald Kates, Laia Paré, Eva-Maria Grischke, Helmut Forstbauer, Michael Braun, Mathias Warm, John Hackmann, Christoph Uleer, Bahriye Aktas, Claudia Schumacher, Rachel Wuerstlein, Monika Graeser, Enrico Pelz, Katarzyna Jóźwiak, Christine zu Eulenburg, Hans Heinrich Kreipe, Nadia Harbeck, on behalf of the ADAPT TN investigators
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (22): 4995–5003.
https://doi.org/10.1158/1078-0432.CCR-22-0482
Published: 14 November 2022
View article titled, De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial
Open the PDF for De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial in another window
Includes: Supplementary data
Journal Articles

Correction: Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant

Free
Sara M. Tolaney, Masakazu Toi, Patrick Neven, Joohyuk Sohn, Eva-Maria Grischke, Antonio Llombart-Cussac, Hatem Soliman, Hong Wang, Sameera Wijayawardana, Valerie M. Jansen, Lacey M. Litchfield, George W. Sledge, Jr
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (20): 4587.
https://doi.org/10.1158/1078-0432.CCR-22-2874
Published: 14 October 2022
View article titled, Correction: Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant
Open the PDF for Correction: Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant in another window
Journal Articles

Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant

Available to Purchase
Sara M. Tolaney, Masakazu Toi, Patrick Neven, Joohyuk Sohn, Eva-Maria Grischke, Antonio Llombart-Cussac, Hatem Soliman, Hong Wang, Sameera Wijayawardana, Valerie M. Jansen, Lacey M. Litchfield, George W. Sledge, Jr
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (8): 1500–1506.
https://doi.org/10.1158/1078-0432.CCR-21-3276
Published: 14 April 2022
View article titled, Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant
Open the PDF for Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant in another window
Includes: Supplementary data
Journal Articles

MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2−-Advanced Breast Cancer

Available to Purchase
Patrick Neven, Stephen R.D. Johnston, Masakazu Toi, Joohyuk Sohn, Kenichi Inoue, Xavier Pivot, Olga Burdaeva, Meena Okera, Norikazu Masuda, Peter A. Kaufman, Han Koh, Eva-Maria Grischke, PierFranco Conte, Yi Lu, Nadine Haddad, Karla C. Hurt, Antonio Llombart-Cussac, George W. Sledge
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (21): 5801–5809.
https://doi.org/10.1158/1078-0432.CCR-20-4685
Published: 01 November 2021
View article titled, MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2−-Advanced Breast Cancer
Open the PDF for MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2−-Advanced Breast Cancer in another window
Includes: Supplementary data
Journal Articles

A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer

Available to Purchase
Amit M. Oza, Maria Estevez-Diz, Eva-Maria Grischke, Marcia Hall, Frederik Marmé, Diane Provencher, Denise Uyar, Johanne I. Weberpals, Robert M. Wenham, Naomi Laing, Michael Tracy, Tomoko Freshwater, Mark A. Lee, Ji Liu, Jingjun Qiu, Shelonitda Rose, Eric H. Rubin, Kathleen Moore
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (18): 4767–4776.
https://doi.org/10.1158/1078-0432.CCR-20-0219
Published: 15 September 2020
View article titled, A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer
Open the PDF for A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO)

Free
Nicholas C. Turner, Melinda L. Telli, Hope S. Rugo, Audrey Mailliez, Johannes Ettl, Eva-Maria Grischke, Lida A. Mina, Judith Balmaña, Peter A. Fasching, Sara A. Hurvitz, Andrew M. Wardley, Colombe Chappey, Alison L. Hannah, Mark E. Robson
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (9): 2717–2724.
https://doi.org/10.1158/1078-0432.CCR-18-1891
Published: 01 May 2019
View article titled, A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO)
Open the PDF for A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO) in another window
Includes: Supplementary data